|
RAB4A expression based on
|
Statistics: Unpaired two sample T-test was employed to evaluate levels of significance in expression level between any two sample groups
| Comparison | Statistical significance |
| Normal-vs-Primary | 9.198000E-03 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.695100E-03 |
| Normal-vs-Stage2 |
9.995400E-01 |
| Normal-vs-Stage3 |
2.583800E-02 |
| Normal-vs-Stage4 |
1.922380E-01 |
| Stage1-vs-Stage2 |
2.077800E-01 |
| Stage1-vs-Stage3 |
8.338600E-01 |
| Stage1-vs-Stage4 |
7.840600E-01 |
| Stage2-vs-Stage3 |
2.638400E-01 |
| Stage2-vs-Stage4 |
3.790800E-01 |
| Stage3-vs-Stage4 |
8.914800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
9.144000E-03 |
| Normal-vs-AfricanAmerican |
6.307600E-01 |
| Normal-vs-Asian |
3.611100E-04 |
| Caucasian-vs-AfricanAmerican |
7.636100E-02 |
| Caucasian-vs-Asian |
9.915500E-02 |
| AfricanAmerican-vs-Asian |
3.843700E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.605400E-01 |
| Normal-vs-Female |
3.741500E-03 |
| Male-vs-Female |
2.912200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
6.158200E-03 |
| Normal-vs-Age(41-60Yrs) |
9.295900E-03 |
| Normal-vs-Age(61-80Yrs) |
5.751800E-01 |
| Normal-vs-Age(81-100Yrs) |
4.718000E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.882400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.978980E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.391600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.531400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.186400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.957400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
6.725000E-01 |
| Classical-VS-Follicular |
4.440800E-01 |
| Classical-VS-Other |
7.947200E-01 |
| Classical-VS-Normal |
1.125650E-02 |
| Tall-VS-Follicular |
3.411600E-01 |
| Tall-VS-Other |
7.388200E-01 |
| Tall-VS-Normal |
2.332000E-02 |
| Follicular-VS-Other |
9.198000E-01 |
| Follicular-VS-Normal |
3.102800E-01 |
| Other-VS-Normal |
8.996800E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.423000E-03 |
| Normal-vs-N1 |
2.161400E-04 |
| N0-vs-N1 |
1.187560E-01 |
|
|
